Alcobra Ltd. (NASDAQ:ADHD) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel. “
A number of other research firms also recently commented on ADHD. WBB Securities upgraded shares of Alcobra from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a report on Monday. Roth Capital downgraded shares of Alcobra from a “buy” rating to a “neutral” rating and cut their price objective for the company from $4.00 to $1.00 in a report on Friday, September 29th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the company. Alcobra has a consensus rating of “Hold” and an average price target of $1.56.
Alcobra (NASDAQ:ADHD) last released its quarterly earnings data on Friday, August 11th. The biotechnology company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Downgrades Alcobra Ltd. (ADHD) to Hold” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.com-unik.info/2017/10/13/zacks-investment-research-downgrades-alcobra-ltd-adhd-to-hold.html.
Several institutional investors have recently bought and sold shares of ADHD. Citadel Advisors LLC grew its stake in shares of Alcobra by 7,251.0% in the 1st quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 101,514 shares during the period. Worth Venture Partners LLC grew its stake in shares of Alcobra by 35.6% in the 2nd quarter. Worth Venture Partners LLC now owns 271,982 shares of the biotechnology company’s stock valued at $305,000 after buying an additional 71,465 shares during the period. Finally, Royce & Associates LP grew its stake in shares of Alcobra by 15.5% in the 1st quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock valued at $849,000 after buying an additional 100,000 shares during the period. 29.68% of the stock is owned by institutional investors and hedge funds.
Alcobra Company Profile
Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.
What are top analysts saying about Alcobra Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alcobra Ltd. and related companies.